PMC9717427_01
(A) Multiple erythemas and pustules with central clearing and crusted edge located on the face, trunk, and extremities upon initial evaluation. (B) Regression of skin lesions one week after treatment with Adalimumab (80mg/week). (C and D) Regression of skin lesions three weeks and six weeks after treatment with Adalimumab.
CCID-15-2567-g0001.jpg
PMC9717427_01_CCID-15-2567-g0001.jpg
f0001
Clinical examination revealed multiple erythema and pustules were present on the face, trunk, and extremities (Figure 1A). After administration, the skin lesions gradually improved within 1 week of the treatment (Figure 1B). After six weeks of follow-up, almost all the lesions subsided, with no new lesions or adverse reactions (Figure 1C and D).
The Subcorneal pustule is composed predominantly of neutrophils, with spongiosis in the granular layer and upper spine layer, and infiltration of neutrophils and lymphocytes in the superficial dermis. (Hematoxylin and eosin; magnifications: (A) x40, (B) x200).
CCID-15-2567-g0002.jpg
PMC9717427_01_CCID-15-2567-g0002.jpg
f0002
A lesional skin biopsy showed a subcorneal pustule composed predominantly of neutrophils, with spongiosis in the granular and upper spine layer and infiltration of neutrophils and lymphocytes in the superficial dermis (Figure 2A and B).